Background: Eltrombopag and romiplostim are thrombopoietin receptor agonists (TPOs) that have been increasingly used for the treatment of immune thrombocytopenia (ITP). Based on our experience, the incidence of abortive treatment with these drugs and the occurrence of adverse reactions that lead to therapy break-off despite response are higher than has been previously suggested. Methods: During the last 8 years, a total of 65 patients were treated with eltrombopag and/or romiplostim at our institute. Results: 36 of a total of 58 patients responded well to eltrombopag. In 12 patients that responded, treatment with eltrombopag was discontinued due to the development of adverse reactions. Eltrombopag was replaced by romiplostim in 23 cases (14 non-responders, 9 patients with adverse reactions). Of these patients, 83% responded to romiplostim. Among all patients treated with romiplostim (n = 32), 75% initially responded; however, 8 of these patients developed adverse reactions. Romiplostim was replaced by eltrombopag in 5 cases (4 due to adverse reactions, 1 non-responsive patient), and only 3 (60%) of these patients were observed to respond to eltrombopag. Conclusion: TPOs often remain ineffective in ITP or result in adverse reactions, which lead to treatment stop or to drug switch. Therefore, alternative treatment options are required.

Keywords:
Autoimmune thrombocytopenia, Eltrombopag, Romiplostim, Thrombopoietin receptor agonists, Adverse reactions
1.
Cines DB, Liebman HA: The immune thrombocytopenia syndrome: a disorder of diverse pathogenesis and clinical presentation. Hematol Oncol Clin North Am 2009;23:1155-1161.
2.
Godeau B, Provan D, Bussel J: Immune thrombocytopenic purpura in adults. Curr Opin Hematol 2007;14:535-556.
3.
Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kühne T, Ruggeri M, George JN: Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386-2393
4.
Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, Grainger J, Greer I, Hunt BJ, Imbach PA, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino M, Watson S, Young J, Kuter DJ: International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168-186.
5.
Salama A: Current treatment options for primary immune thrombocytopenia. Expert Rev Hematol 2011;4:107-118.
6.
Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, Liebman HA, Slovick FT, de Wolf JT, Bourgeois E, Guthrie TH Jr, Newland A, Wasser JS, Hamburg SI, Grande C, Lefrère F, Lichtin AE, Tarantino MD, Terebelo HR, Viallard JF, Cuevas FJ, Go RS, Henry DH, Redner RL, Rice L, Schipperus MR, Guo DM, Nichol JL: Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008;371:395-403.
7.
Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL: Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009;113:2161-2171. Erratum in Blood 2009;113:4822.
8.
Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, Rodeghiero F, Chong BH, Wang X, Berger DP: Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010;363:1889-1899.
9.
Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB: Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011;377:393-402.
10.
Khellaff M, Michel M, Quittet P, Viallard JF, Alexis M, Roudot-Thoraval F, Cheze S, Durand JM, Lefrère F, Galicier L, Lambotte O, Panelatti G, Slama B, Damaj G, Sebahoun G, Gyan E, Delbrel X, Dhedin N, Royer B, Schleinitz N, Rossi JF, Mahévas M, Languille L, Bierling P, Godeau B: Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in aromiplostim compassionate-use program. Blood 2011;118:4338-4345.
11.
Bussell JB, Buchanan GR, Nugent DJ, Gnarra DJ, Bomgaars LR, Blanchette VS, Wang YM, Nie K, Jun S: A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood 2011;118:28-36.
12.
Kuter DJ, Bussel JB, Newland A, Baker RI, Lyons RM, Wasser J, Viallard JF, Macik G, Rummel M, Nie K, Jun S: Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol 2013;161:411-423.
13.
Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A; EXTEND Study Group: Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 2013;121:537-545.
14.
Zinsmeister AR, Connor JT: Ten common statistical errors and how to avoid them. Am J Gastroenterol 2008;103:262-266.
15.
Strasak AM, Zaman Q, Pfeiffer KP, Göbel G, Ulmer H: Statistical errors in medical research - a review of common pitfalls. Swiss Med Wkly 2007;137:44-49.
16.
Bengston WF, Moga M; Resonance, Placebo effects, and type II errors: some implications from healing research for experimental methods. J Altern Complement Med 2007;13:317-327.
17.
Newton JL, Reese JA, Watson SI, Vesely SK, Bolton-Maggs PH, George JN, Terrell DR: Fatigue in adult patients with primary immune thrombocytopenia. Eur J Haematol 2011;86:420-429.
18.
Hill QA, Newland AC: Fatigue in immune thrombocytopenia. Br J Haematol 2015;170:141-149.
19.
Matzdorff AC, Arnold G, Salama A, Ostermann H, Eberle S, Hummler S: Advances in ITP-therapy and quality of life-a patient survey. PLoS One 2011;6:e27350.
20.
Ghanima W, Geyer JT, Lee CS, Boiocchi L, Imahiyerobo AA, Orazi A, Bussel JB: Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up. Haematologica 2014;99:937-944.
21.
Kuter DJ, Macahilig C, Grotzinger KM, Poston SA, Wang PF, Dawson KL, Ward M: Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim. Int J Hematol 2015;101:255-263.
22.
González-Porras JR, Mingot-Castellano ME, Andrade MM, Alonso R, Caparrós I, Arratibel MC, Fernández-Fuertes F, Cortti MJ, Pascual C, Sánchez-González B, Bernat S, Fuertes-Palacio MA, Vázquez-Paganini JA, Olivera PE, Alvarez-Román MT, Jarque I, Cortés M, Martínez-Robles V, Díaz-Gálvez FJ, Calbacho M, Fernández-Miñano C, Garcia-Frade J, González-López TJ: Use of eltrombopag after romiplostim in primary immune thrombocytopenia. Br J Haematol 2015;169:111-116.
23.
Tsukamoto S, Nakaseko C, Takeuchi M, Kumagai K, Komatsu T, Tanaka H, Hara S, Koizumi M, Imai H, Yokota A, Takeuchi M, Inokuchi K, Matsuura Y, Aotsuka N, Wakita H: Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia. Br J Haematol 2013;163:286-289.
24.
Khellaf M, Viallard JF, Hamidou M, Cheze S, Roudot-Thoraval F, Lefrere F, Fain O, Audia S, Abgrall JF, Michot JM, Dauriac C, Lefort S, Gyan E, Niault M, Durand JM, Languille L, Boutboul D, Bierling P, Michel M, Godeau B: A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica 2013;98:881-887.
25.
Cooper KL, Fitzgerald P, Dillingham K, Helme K, Akehurst R: Romiplostim and eltrombopag for immune thrombocytopenia: methods for indirect comparison. Int J Technol Assess Health Care 2012;28:249-258.
26.
Ghanima W, Geyer JT, Lee CS, Boiocchi L, Imahiyerobo AA, Orazi A, Bussel JB: Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long term follow up. Haematologica 2014;99:937-944.
27.
Rizvi H, Butler T, Calaminici M, Doobaree IU, Nandigam RC, Bennett D, Provan D, Newland AC: United Kingdom immune thrombocytopenia registry: retrospective evaluation of bone marrow fibrosis in adult patients with primary immune thrombocytopenia and correlation with clinical findings. Br J Haematol 2015;169:590-594.
© 2016 S. Karger GmbH, Freiburg
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.